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A B S T R A C T
Clonal haematopoiesis of indeterminate potential (CHIP) is widespread in the elderly. CHIP is driven by somatic
mutations in leukaemia driver genes, such as Janus Kinase 2 (JAK2), Tet methylcytosine dioxygenase 2 (TET2),
ASXL Transcriptional Regulator 1 (ASXL1) and DNA (cytosine-5)-methyltransferase 3A (DNMT3A), leading to
reduced diversity of the blood pool. CHIP carries an increased risk for leukaemia and cardiovascular disease.
Apart from mutations driving CHIP, environmental factors such as chemokines and cytokines have been im-
plicated in age-dependent multimorbidities associated with CHIP. However, the mechanism of CHIP onset and
the relationship with environmental and cell-intrinsic factors remain poorly understood. Here we contrast cell-
intrinsic and environmental factors involved in CHIP development and disease propagation.
1. Introduction
Age is the single most significant factor underlying the onset of
many haematological malignancies (de Magalhães, 2013), with changes
in the clonal composition towards a myeloid bias commonly occurring
with advanced age (Cho et al., 2008). The onset of clonal haemato-
poiesis of indeterminate potential (CHIP) in the haematopoietic stem
and progenitor cell (HSPC) compartment is also associated with hae-
matological malignancies (Genovese et al., 2014). CHIP is apparent in
the general population from age 60 with a steady increase in prevalence
to 18–20% of individuals aged over 90 years at 2% variant allele fre-
quency (VAF) (McKerrell et al., 2015). CHIP is driven by somatic mu-
tations in leukaemic driver genes, thereby reducing the diversity of the
stem cell pool. Epigenetic modifiers such as TET2, ASXL1 and DNMT3A
are the most frequently mutated genes in CHIP. TET2 and DNMT3A are
epigenetic regulators involved in DNA methylation impacting self-re-
newal and differentiation capacities of haematopoietic stem cells
(HSCs) while ASXL1 - a member of the polycomb repressive complex - is
involved in chromatin remodelling and affects hematopoietic re-
populating capacity and expansion of the haematopoietic stem cell
compartment (Bowman et al., 2018; Challen et al., 2011; Fuster et al.,
2017; Jeong et al., 2018; Ko et al., 2011; Li et al., 2011; Lu et al., 2016;
Mayle et al., 2015; Moran-Crusio et al., 2011; Pan et al., 2017;
Quivoron et al., 2011; Wang et al., 2014). Interestingly, one hallmark of
ageing is the global loss of methylation and profound changes to het-
erochromatin (Chandra and Kirschner, 2016; Cypris et al., 2019).
JAK2V617F is a common synonymous variant that is frequently
mutated in CHIP and age-related myeloid malignancies (Chen et al.,
2012), where the JAK2 tyrosine phosphatase is constitutively activated
driving a plethora of downstream pathways such as the phosphoinosi-
tide-3-kinase/Protein kinase B pathway (PI3K/AKT), Signal Transdu-
cers and Activators of Transcription (STAT) and RAS/RAF/MEK/ERK
Mitogen-activated protein kinase pathways. Together these pathways
confer a proliferative advantage, resistance to DNA damage mediated
apoptosis and can activate an inflammatory response (Chen et al.,
2012).
DNA damage response and stress-related genes Tumour Suppressor
53 (TP53) and Protein Phosphatase, Mg2+/Mn2+ Dependent 1D
(PPM1D) are another class of mutations identified in CHIP (Genovese
et al., 2014; McKerrell et al., 2015). TP53 and PPM1D mutations are
predominantly mutated in leukocytes of patients who have undergone
cancer treatment for solid tumours and display clonal haematopoiesis
(Coombs et al., 2017), associating genotoxic stress with clonal selec-
tion. In this study, clonal haematopoiesis was associated with secondary
leukaemia development following solid cancer therapy. In other studies
elucidating the mechanism of mutant PPM1D in clonal haematopoiesis
and subsequent therapy-related myeloid malignancies (Hsu et al., 2018;
Kahn et al., 2018), mutant PPM1D seemed to confer resistance to
apoptosis in the context of genotoxic stress. Therapy-induced senes-
cence is a prominent feature in cancer therapy and an alternative me-
chanism of cancer therapy resistance, with TP53 being one of the most
prominent senescence inducers, engaging a specific, downstream se-
nescence programme that differs profoundly from apoptosis (Kahlem
et al., 2004; Kirschner et al., 2015). Whether TP53 mutations shift the
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pathway away from apoptosis towards senescence in the context of
CHIP remains to be elucidated.
Lastly, splicing factors emerge late in the pathogenesis of CHIP with
the most prominent being Splicing Factor 3b Subunit (SF3B1), SRSF2
(Serine and Arginine Rich Splicing Factor 2) and U2 Small Nuclear RNA
Auxiliary Factor 1 (U2AF1) (Inoue et al., 2016). These mutations alter
RNA splicing in a sequence-specific manner and might affect down-
stream pathways leading to CHIP over a longer period of time.
CHIP is associated with an increased risk for haematological cancers
and all-cause mortality, specifically coronary heart disease and
ischaemic stroke, for which age is a major risk factor (Genovese et al.,
2014; Jaiswal et al., 2017, 2014; McKerrell et al., 2015; Zink et al.,
2017). In addition, CHIP in patients with heart failure results in in-
creased mortality and hypertension (Dorsheimer et al., 2019). In this
review, we will discuss factors that can lead to the onset of CHIP and its
age-associated diseases contrasting fitness acquired by mutations (cell-
intrinsic) against cell-extrinsic changes in the ageing environment.
2. Cell-intrinsic contributions to CHIP
Several landmark studies reported the occurrence of CHIP in
healthy aged individuals using various deep sequencing approaches of
peripheral blood mononuclear cells (PBMCs). The major driver muta-
tions, such as JAK2, TET2 and DNMT3A, in all cohorts examined
overlap, with varying allele frequencies of the distinct driver mutations.
A few genes were only reported in some cohorts, such as the DNA da-
mage response pathway gene PPM1D (Genovese et al., 2014; Jaiswal
et al., 2017, 2014; McKerrell et al., 2015). The occurrence of CHIP
mutations with age pointed to a time-dependent acquisition pattern,
leading to a competitive advantage and driving CHIP with advanced
age (Fig. 1). This is especially true when considering splicing factors.
Mouse studies of commonly mutated CHIP genes support the notion
that clonal outgrowth is driven by cell-intrinsic properties in the HSPC
compartment. Among the most frequently mutated genes is Dnmt3a.
Challen and colleagues demonstrated that conditional loss of Dnmt3a in
HSCs impairs their differential potential by altering DNA methylation
(Challen et al., 2011). In knockout mice, loss of Dnmt3a immortalises
HSCs (Jeong et al., 2018), leading to skewed division potential with
HSCs being primed towards self-renewal for up to twelve rounds of
transplantation with gradual and focal loss of DNA methylation at key
HSC self-renewal sites. In this study, however, transformation required
additional mutations (Jeong et al., 2018). In a study by Mayle et al.,
transplantation of murine Dnmt3a-knockout HSCs into irradiated wild-
type mice resulted in the development of a range of haematological
malignancies, leading to increased mortality. These results suggest a
cell-intrinsic role of Dnmt3a loss in HSCs in acquiring a preleukemic
state (Mayle et al., 2015). This is in accordance with another mouse
study, where HSPCs with a DNMT3aR882H mutation, the most com-
monly found CHIP mutation, promotes leukaemia only in the presence
of other oncogenes such as N-RasG12D (Lu et al., 2016).
DNMT3aR882H alone led to hypomethylation at cis-elements of es-
sential stemness genes such as the Meis Homeobox 1 (Meis1), MN1
proto-oncogene (Mn1), and Hoxa gene clusters, and led to increased
expression of a panel of stemness genes (Lu et al., 2016).
TET2 is also commonly mutated in individuals with CHIP. Several
studies using Tet2 knockout and mutant mouse models have explored
cell-intrinsic mechanisms of HSCs leading to malignant transformation
(Ko et al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011). All
these studies showed an expansion of the HSC compartment, as well as
enhanced self-renewal potential associated with TET2 loss-of-function.
Interestingly, Li and colleagues demonstrated an increase of the murine
HSC pool in Tet2 knockout mice, with only a subset of mice developing
myeloid malignancies (Li et al., 2011). A later study showed sponta-
neous development of different haematological malignancies in Tet2
knockout mice, resulting from increased mutagenicity (Pan et al.,
2017). Single-cell -targeted sequencing revealed a higher mutation rate
in Tet2-/- HSPCs particularly at sites which gained 5-hydro-
xymethylcytosine, suggesting TET2 mediated cell-intrinsic changes in
HSPCs leading to malignant transformation (Pan et al., 2017).
It is well documented that CHIP mutations can result in inflamma-
tion, leading to, for example, enhanced atherosclerosis. In this context,
Jaiswal and colleagues (Jaiswal et al., 2014) showed that, when
atherosclerosis prone mice were transplanted with Tet2 knockout bone
marrow cells, the development of atherosclerosis was markedly ac-
celerated on the background of a high cholesterol, high-fat diet. In
addition, higher levels of pro-inflammatory chemokines could be de-
tected in the serum of these mice. On the molecular level, Tet2 knockout
macrophages, when cultured with low-density lipoprotein, displayed a
highly inflammatory transcriptional signature compared to wild type
(WT) macrophages, suggesting the involvement of inflammatory sig-
nalling in the progression of atherosclerosis on a Tet2 mutant back-
ground. In addition, Fuster and colleagues studied the effects of Tet2
mutant HSPCs and their progeny in atherosclerosis prone mice deficient
in low-density lipoprotein receptor (Ldlr–/–) by competitive
Fig. 1. Is CHIP dependent on the environment or driven by cell intrinsic
factors?
Upper panel: CHIP is driven cell-intrinsically. Here, the time to acquisition of
the CHIP mutation (Mut.) and the change in fitness conferred by the mutation
are the determining factors of clonal outgrowth. Average time to mutation
depends on a variety of factors, including sequence context of the mutation,
mutation rate and genotoxic events, such as chemotherapy.
Lower Panel: CHIP is driven through cell-intrinsic and environmental
factors. Here, the time to acquisition of the CHIP mutation (Mut.) and the
change in fitness conferred by the mutation are again determining factors.
However, clonal outgrowth is enhanced or enabled by environmental changes
(Env. yellow background). Supposed environmental factors are discussed in the
main text and include inflammation and other age-related changes.
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transplantation (Fuster et al., 2017). The authors demonstrated that
TET2 loss of function in macrophages exacerbated NLR Family Pyrin
Domain Containing 3 (Nlrp3) mediated Interleukin 1 beta (IL-1b) pro-
duction which in turn accelerated atherosclerosis in a context of CHIP,
thereby demonstrating that CHIP leads to increased inflammation. In-
flammation resulting from mutations in CHIP associated genes is fur-
ther evidenced by a mouse study, examining the co-operating onco-
genic effects of Jak2V617F and Dnmt3a in HSPCs (Jacquelin et al.,
2018). Dnmt3a loss on top of the Jak2V617F mutation led to the acti-
vation of inflammatory signalling, inducing myelofibrosis. A recent
study showed that the Jak2V617F mutation in HSPCs gave rise to cir-
culating myeloid cells with enhanced pro-inflammatory properties on
its own in mouse models of cardiac injury (Sano et al., 2019). These
studies demonstrate a role for cell-intrinsic activation of inflammatory
pathways as a consequence of CHIP.
Modelling approaches contribute further to evidence for mutations
alone being able to explain CHIP. Watson and colleagues (Watson et al.,
2020) used PBMC sequencing data from various CHIP studies, analysing
50,000 individuals at varying VAFs. They showed that modelling clone
size distributions based on a change of fitness conferred by driver
mutations and the probability (time) to acquire these mutations was
enough to predict the observed distributions from the collected data
sets.
3. Contributing environmental factors towards CHIP
Systemic inflammation from the environment can promote CHIP
through, for example, short term inflammatory stress caused by lipo-
polysaccharides in HSPCs (Cai et al., 2018) (Fig. 1). Murine Tet2
knockout HSPCs display a survival advantage compared to WT HPSCs
during acute inflammation. Following inflammation, Tet2 knockout
HSPCs activated the interleukin 6 (Il6) mediated Stat3/Morbid axis,
leading to the upregulation of B-cell lymphoma 2 (Bcl2) pro-survival
factor and reduced apoptosis in these cells. Therefore, cell-extrinsic
factors such as an inflammatory milieu can enhance the competitive
fitness of CHIP mutant HSPCs over time.
DNA damage accumulates in aged HSCs and leads to decreased stem
cell function. One study linked increased DNA damage directly to exit
from the homeostatic quiescent state of HSCs as a response to physio-
logical stresses, explaining the accumulation of DNA damage in aged
HSC (Walter et al., 2015). The authors used polyinosinic:polycytidylic
acid to mimic viral infections, effectively mounting a type I interferon
response (Walter et al., 2015). In addition, a recent study implicated
Rad21/Cohesin mediated NFkB signalling in aged HSCs with loss of
self-renewal in favour of myeloid biased differentiation in response to
inflammatory stimuli (Chen et al., 2019). Inflammation-induced exit
from quiescence and ageing-associated inflammation in blood serum
and tissue could, therefore, influence the selection of mutant HSPCs
carrying CHIP mutations.
A small study in 187 ulcerative colitis (UC) patients, an autoimmune
disease characterised by increased levels of proinflammatory cytokines
with an average onset age before 30 years, analysed targeted PBMC
sequencing for CHIP mutations (Zhang et al., 2019). Albeit patient
numbers being small and the lack of a validation cohort, the study re-
vealed DNMT3A and PPM1D as the most prevalent mutations with a
lower incidence of TET2 mutations. In this cohort, overall CHIP was
slightly higher in UC patients, with DNMT3A mutant patients revealing
significantly higher levels of serum interferon-gamma (IFNg), but not
tumour necrosis factor-alpha. Interestingly, DNMT3A VAF was a sig-
nificant contributor to increased IFNg levels, suggesting that increased
IFNg might select for DNMT3A mutations in UC. Given that the onset of
UC mostly occurs before the age of 30 years - compared to the onset of
CHIP occurring at least two decades later, this study might provide
evidence of a pro-inflammatory milieu playing a role in CHIP onset (Ha
et al., 2010). However, in a minority of UC patients, disease occurs at
the age of 50 years or older. In this context, inflammation might occur
first, resulting from, for example, DNMT3A mutant T-cell clones
(Thomas et al., 2010) or other CHIP related inflammatory processes as
discussed above.
4. Associations with CHIP
Most CHIP studies describe associations with age-related multi-
morbidities or ageing factors, leaving uncertainty over cell-intrinsic
versus environmental factors and their contributions to CHIP.
A key determinant of CHIP is the presence of recurrent driver mu-
tations that are functionally well described; however, many samples
frequently present with not known causal variants - a phenomenon
known as clonal haematopoiesis with unknown drivers (CH-UD)
(Genovese et al., 2014). Genovese and colleagues performed whole-
exome sequencing of PBMCs on 11,845 participants, where the majority
had not known putative driver mutations, with 1333 participants dis-
playing 1 mutation, 313 participants harbouring 2 mutations, and 272
with 3 to 18 somatic mutations in total (Genovese et al., 2014). The
authors then defined CH-UD based on the mutational burden in pas-
senger genes alone, rather than on the identity of the mutations. In
some participants without known driver mutations, further analysis and
deeper sequencing eventually revealed a candidate variant (Genovese
et al., 2014), suggesting that detection sensitivity might have been
limiting in the first instance. The absence of canonical CHIP variants
might also be explained by copy-number alterations of affected genes;
however, it is unlikely that these factors explain all cases. Indeed, some
have hypothesised CH-UD may be linked to reduced HSC fitness with
age which results in increased oligoclonality through a depletion of the
HSC pool (Gibson and Steensma, 2018).
Robertson and colleagues (Robertson et al., 2019) recently showed
an increase in epigenetic age, a correlate of biological age, in CHIP
carriers when compared to individuals without detectable CHIP. In this
study, CHIP mutations were annotated in the Lothian Birth Cohorts
(LBCs) of 1921 (n = 550) and 1936 (n = 1091), two independent,
longitudinal studies in the elderly using whole-genome sequencing.
Epigenetic clock analysis was then performed on 450 K methylation
arrays. Increased epigenetic age was noted when considering all CHIP
mutations together, and TET2 and DNMT3A mutations individually.
These effects were larger than the known sex differences in age accel-
eration (male > female) in either cohort. Moreover, VAF was positively
correlated with accelerated epigenetic age, suggesting a link to clone
size, which could be driven by intrinsic or environmental factors.
Zink and colleagues performed deep whole-genome sequencing
(WGS) in 11,262 Icelanders and identified 1403 cases of CHIP at 2%
VAF, irrespective of driver mutation status (Zink et al., 2017). Overall
CHIP in this cohort was much more common compared to other studies,
with 50% of participants over the age of 85 being carriers, showing
similar somatic mutation patterns as previously reported (TET2,
DNMT3A, ASXL1, PPM1D). In this cohort, CHIP mutations were asso-
ciated with reduced telomere length (Zink et al., 2017). This finding
complements the notion that epigenetic age is altered in CHIP, sug-
gesting that proliferation might be a feature contributing to cell-in-
trinsic ageing factors and systemic ageing. Interestingly, known driver
mutations were only apparent in a fraction of CHIP carriers. Using
modelling approaches, the authors suggested that some clones have
arisen in the absence of mutations as a result of neutral drift, which
would only act on a small number of active HSCs. However, the ma-
jority of CHIP cases in the absence of mutations remained unexplained,
suggesting environmental influences.
Further evidence for clonal outgrowth due to increased age comes
from a study where WGS of PBMCs from a 115-year-old woman was
performed (Holstege et al., 2014). The authors detected 450 somatic
mutations, which were reported as passenger mutations, leading to
oligoclonal haematopoiesis (Holstege et al., 2014). The authors sug-
gested that the finite lifespan of HSCs leads to CHIP rather than the
acquisition of driver mutations. Whether HSC lifespan is mainly
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regulated by environmental (e.g. cytokines promoting proliferation) or
cell-intrinsic factors (e.g. telomere length) remains to be seen. During
ageing, senescence due to telomere shortening or other cues has been
described as a main driver of a proinflammatory environment (Acosta
et al., 2008; Coppé et al., 2008; Kuilman et al., 2008). Telomere
shortening in bone marrow stromal cells was correlated with a dys-
functional haematopoietic environment and increased cytokines in
ageing context (Ju et al., 2007). Whether senescence and SASP play a
significant role during ageing of the blood compartment remains to be
conclusively elucidated.
5. Concluding remarks
It is becoming increasingly clear that certain mutations lead to
CHIP. For TET2 and SRSFP95H mutations, myeloid bias was associated
with CHIP or the initiation of myelodysplastic/myeloproliferative syn-
drome, whereas for DNMT3A multipotent stem cell origin was de-
scribed in the context of CHIP (Buscarlet et al., 2018; Smeets et al.,
2018). However, competition or cooperation between clones of distinct
sizes, lineage origin and different types of mutations is currently un-
known. For example, could an early clone create an environment fa-
vouring outgrowth of certain other clones over time, by, for example,
promoting inflammation?
Although evidence is increasing for mutations driving CHIP, several
studies also suggest clonal outgrowth can appear in the absence of
driver mutations. One such scenario could be due to a selection based
on transcriptional phenotypes in the absence of CHIP, as suggested for
ageing mouse HSCs. In one study, only a minority subpopulation of
HSCs developed transcriptional signatures commonly associated with
HSC ageing such as Tp53 (Kirschner et al., 2017). The majority of HSCs
showed a transcriptome similar to that of young HSCs, suggesting
heterogeneous ageing phenotypes on the transcriptional level
(Kirschner et al., 2017). Whether proliferation of HSC subpopulations
was driven cell-intrinsically, or whether HSC subpopulations were
simply being kept in a low proliferative state over time, gaining an
advantage over exhausted, pro-proliferative HSC populations with in-
creased age, remains to be elucidated.
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